This toolkit presents a children's health care quality measure from the AHRQ-CMS Pediatric Quality Measures Program (PQMP). The measure has been developed by PQMP Centers of Excellence (COE) grantee, the National Collaborative for Innovation in Quality Measures (NCINQ), a consortium of organizations committed to advancing measurement of pediatric health care. NCINQ is led by the National Committee for Quality Assurance (NCQA) in partnership with New York University Langone Health (NYU) and Youth MOVE National (YMN).
The change ideas, resources, and examples presented in this toolkit reflect efforts by state Medicaid agencies, health plans, and practices to improve performance on the Healthcare Effectiveness Data and Information Set (HEDIS庐 i) antipsychotics measures developed by NCINQ.
This toolkit includes materials to support users in working towards improvement in the safe and judicious use of antipsychotic medications (first and second generation) in children and adolescents. Specifically, the toolkit includes:
- A collection of strategies and change ideas for health plans, practices, and providers to choose from when working towards improvement;
- Actions health plans can take to make improvements; and,
- Options that states, plans, providers, and patients and their families can apply during process improvement efforts.
The intended audiences for this toolkit are health plans, medical practices and providers.
This toolkit is organized into five (5) sections:
The key drivers, change ideas, and resources provided are intended to serve as options that states, plans, providers, and patients and their families can apply. Process improvement teams can reference the key driver diagrams to brainstorm and implement change ideas, as well as consult QI Best Practices for the Safe and Judicious Use of Antipsychotic in Children and Adolescents as a roadmap for improvement. For detailed information on guidelines and recommendations specific to the measures included in this toolkit, refer to Guidelines and Recommendations for the Safe and Judicious Use of Antipsychotic Medications in Children and Adolescents.
____________________
i. HEDIS is a registered trademark of the National Committee for Quality Assurance.
